Published in Br J Cancer on July 25, 2005
Biology and management of pancreatic cancer. Gut (2007) 2.53
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol (2012) 2.38
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci (2008) 1.23
Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol (2011) 1.13
Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J Exp Clin Cancer Res (2009) 1.00
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol (2010) 1.00
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer (2009) 0.98
Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics (2011) 0.95
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer (2009) 0.93
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. Invest New Drugs (2009) 0.91
Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol (2011) 0.89
Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol (2010) 0.87
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets (2012) 0.86
Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol (2010) 0.86
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs (2011) 0.85
Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol (2012) 0.84
Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. World J Surg (2011) 0.80
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol (2013) 0.80
Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma. Chin J Cancer Res (2011) 0.78
ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. Int J Clin Oncol (2011) 0.78
How I treat pancreatic ductal adenocarcinoma. J Oncol Pract (2008) 0.75
The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol (2016) 0.75
Serum CA19-9 in patients with solid pancreatic mass. Gastroenterol Hepatol Bed Bench (2013) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol (2003) 4.56
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem (1983) 3.91
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol (1990) 3.20
Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer (2002) 1.58
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer (2000) 1.56
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys (2003) 1.39
Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys (1998) 1.28
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (1996) 1.27
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie (2003) 1.17
CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res (2003) 1.14
Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer (2001) 1.11
Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology (1998) 1.04
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36
Multiple DNA fragment polymorphisms associated with immunoglobulin mu chain switch-like regions in man. Proc Natl Acad Sci U S A (1983) 3.07
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem (1986) 2.93
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 2.93
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol (1997) 2.75
Prevalence and magnitude of perinatal substance exposures in California. N Engl J Med (1993) 2.42
AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology (1999) 2.34
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res (2001) 2.27
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol (2001) 2.24
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol (1999) 1.92
Cloning, tissue distribution, genomic organization, and functional characterization of NBC3, a new member of the sodium bicarbonate cotransporter family. J Biol Chem (1999) 1.92
Cultivable anaerobic microbiota of severe early childhood caries. J Clin Microbiol (2011) 1.85
Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol (2009) 1.83
Molecular cloning, chromosomal localization, tissue distribution, and functional expression of the human pancreatic sodium bicarbonate cotransporter. J Biol Chem (1998) 1.83
Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann Surg Oncol (1998) 1.78
The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas (1996) 1.68
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res (1999) 1.60
The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Intern Med (1992) 1.59
A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol (2000) 1.58
A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother (2001) 1.55
26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem (2001) 1.50
Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med (2001) 1.47
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res (2001) 1.46
Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res (1999) 1.45
Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation. Ann Surg Oncol (1999) 1.42
Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res (2001) 1.42
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene (2001) 1.41
Production and release of proopiomelanocortin (POMC) derived peptides by human melanocytes and keratinocytes in culture: regulation by ultraviolet B. Biochim Biophys Acta (1996) 1.39
A white paper: the product of a pancreas cancer think tank. Cancer Res (2001) 1.39
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. Int J Radiat Oncol Biol Phys (1995) 1.39
Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J Lipid Res (1994) 1.36
SQUID-based microwave cavity search for dark-matter axions. Phys Rev Lett (2010) 1.36
HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc Natl Acad Sci U S A (1998) 1.36
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg (1996) 1.35
Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res (1997) 1.34
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol (1991) 1.33
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32
Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. J Gen Intern Med (1987) 1.30
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol (1998) 1.29
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (1996) 1.27
Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res (1997) 1.27
Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis (2000) 1.26
Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg (1994) 1.25
Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg (2000) 1.24
Preparation and properties of pure tubulin S. Cell Motil Cytoskeleton (1999) 1.24
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol (1990) 1.20
Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res (1999) 1.18
p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci (2000) 1.16
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene (1999) 1.15
Persistence of ferroelectricity in BaTiO3 through the insulator-metal transition. Phys Rev Lett (2010) 1.15
Structure-function analysis of BfpB, a secretin-like protein encoded by the bundle-forming-pilus operon of enteropathogenic Escherichia coli. J Bacteriol (2001) 1.15
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer (2013) 1.12
Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile. Mod Pathol (1996) 1.10
Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery (1995) 1.09
LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res (1997) 1.09
Characterization of GTPase activity of TrmE, a member of a novel GTPase superfamily, from Thermotoga maritima. J Bacteriol (2000) 1.08
Unknown primary tumors metastatic to liver. J Clin Oncol (1998) 1.06
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol (1994) 1.05
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs (1996) 1.05
Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res (2000) 1.05
In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res (2001) 1.05
Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res (1999) 1.04
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology (2012) 1.04
Regulation of cyclin D1, DNA topoisomerase I, and proliferating cell nuclear antigen promoters during the cell cycle. Gene Expr (1995) 1.04
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol (2001) 1.03
Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur J Biochem (2000) 1.03
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg (2000) 1.02
Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin. FEBS Lett (1995) 1.02
DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res (1998) 1.01
bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res (1996) 1.01
Characterization of the heme in human cystathionine beta-synthase by X-ray absorption and electron paramagnetic resonance spectroscopies. Biochemistry (2000) 1.01
A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis (2001) 1.01
CBP80-promoted mRNP rearrangements during the pioneer round of translation, nonsense-mediated mRNA decay, and thereafter. Cold Spring Harb Symp Quant Biol (2011) 1.00
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol (2002) 0.99
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol (2000) 0.98
Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol (2001) 0.98
Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL. J Lipid Res (1995) 0.98
Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem (2001) 0.97
Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res (1988) 0.97
Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. J Interferon Cytokine Res (2000) 0.97
Hepatocellular carcinoma. Curr Opin Oncol (2000) 0.96
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol (1998) 0.96
Duck plague on the American continent. Avian Dis (1968) 0.96
Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol (1996) 0.96
Potentiation by the tetraphenylboron anion of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its pyridinium metabolite. J Neurochem (1990) 0.96
The expression of proopiomelanocortin (POMC) and of corticotropin releasing hormone receptor (CRH-R) genes in mouse skin. Biochim Biophys Acta (1996) 0.96
Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep (2001) 0.96
Perinatal drug use among immigrant and native-born Latinas. Subst Use Misuse (1997) 0.96
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys (2001) 0.95
Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery (1998) 0.95
Report from the Maryland Epidemiology Schizophrenia Linkage Study: no evidence for linkage between schizophrenia and a number of candidate and other genomic regions using a complex dominant model. Am J Med Genet (1994) 0.95
Structural studies of the final enzyme in the alpha-aminoadipate pathway-saccharopine dehydrogenase from Saccharomyces cerevisiae. J Mol Biol (2007) 0.94
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer (2013) 0.94
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. Int J Radiat Oncol Biol Phys (2001) 0.94
Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. Cancer Res (2001) 0.94